Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abicipar pegol - Allergan/Molecular Partners AG

Drug Profile

Abicipar pegol - Allergan/Molecular Partners AG

Alternative Names: AGN-150998; Anti-VEGF DARPin®; DARPin® anti-VEGF product for eye disorders - Molecular Partners/Allergan; MP-0112

Latest Information Update: 18 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Partners AG
  • Developer Allergan; Molecular Partners AG
  • Class Eye disorder therapies; Peptides; Polyethylene glycols; Proteins
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Wet age-related macular degeneration
  • Phase II Diabetic macular oedema

Most Recent Events

  • 11 Oct 2019 Pooled results from the phase III CEDAR and SEQUOIA trials for Wet age-related macular degeneration released by Allergan
  • 09 Sep 2019 Allergan anticipates approval from the US FDA for abicipar pegol in Wet-age related macular degeneration in mid 2020
  • 09 Sep 2019 US FDA accepts BLA for abicipar pegol for Wet age-related macular degeneration for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top